Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Satraplatin - Yakult Honsha

Drug Profile

Satraplatin - Yakult Honsha

Alternative Names: BMS 182751; BMY 45594; JM-216; Orplatna

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Johnson Matthey; The Institute of Cancer Research
  • Developer Agennix AG; Shanghai Jiao Tong University; Yakult Honsha
  • Class Antineoplastics; Cyclohexylamines; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer; Squamous cell cancer
  • Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 09 Apr 2021 No development reported - Phase-I/II for Squamous cell cancer (Inoperable/Unresectable, Late-stage disease) in Japan (PO)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Neoadjuvant therapy) in China (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Second-line therapy or greater) in Japan (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top